NCT05693831

myCare-102: Clinical Utility and Usability of Cellworks Singula™ and Cellworks Ventura™ Reports

myCare-102: A Survey of Physician and Molecular Tumor Board Perspectives on the Clinical Utility and Usability of Cellworks Singula™ and Cellworks Ventura™ Reports in Facilitating Patient Treatment Decisions for Pan-Cancer Patients

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 730 (estimated)
• Sponsor: Cellworks Group Inc. · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the benefit of Cellworks Singula™ reports on physician and molecular tumor board treatment recommendations across a large set of pan-cancer indications who have already received first-line therapy. The study is also to determine the benefit of Cellworks Ventura™ reports on physician and molecular tumor board treatment recommendations across a large set of relapsed or refractory pan-cancer indications. The primary objective of this study is to survey physicians and molecular tumor board perspectives of the benefit of Cellworks Singula™and Cellworks Ventura™ reports in facilitating treatment decisions in pan-cancer patients. Cellworks reports aim to provide NGS-based therapy recommendations to aid the decision-making of patients, physicians, and molecular tumor boards. Cellworks reports aim to provide NGS-based therapy recommendations to aid the decision-making of patients, physicians, and molecular tumor boards.

Conditions

• Cancer
• Relapsed Cancer
• Refractory Cancer

Interventions

Type	Name	Description
OTHER	Cellworks Report	Survey physicians and molecular tumor board perspectives of the benefit of Cellworks Singula™ and Ventura™ reports in facilitating treatment decisions in pan-cancer patients.

Timeline

• Start date: 2022-12-01
• Primary completion: 2024-04-01
• Completion: 2025-12-01
• First posted: 2023-01-23
• Last updated: 2023-01-23

Locations

1 site across 1 country: United States